Kat Kayser-Bricker Honored with Entrepreneur of the Year Award
Shipman celebrates a premier event at a new life sciences hub, honoring innovative entrepreneurs.
Celebrating Innovative Leadership in Life Sciences
In a significant recognition of excellence in the life sciences realm, Kat Kayser-Bricker, Ph.D. has been awarded the esteemed Entrepreneur of the Year Award. This honor is presented by BioCT and Shipman & Goodwin LLP. As the Chief Scientific Officer at Halda Therapeutics, Dr. Kayser-Bricker’s focus on precision-cancer therapies highlights her commitment to improving human health.
Background on the Award
The Entrepreneur of the Year Award, established in 2013, acknowledges the outstanding achievements of entrepreneurs making a difference in the life sciences. The award is a testament to the transformative power of visionaries like Dr. Kayser-Bricker, who significantly impact the industry and community.
"Kat has been a transformative innovator in the life sciences ecosystem," noted Dormer Stephen, Partner at Shipman and a board member of BioCT. This recognition reflects a long-standing partnership aimed at supporting entrepreneurial leaders.
Dr. Kayser-Bricker's Vision and Impact
In accepting the award, Dr. Kayser-Bricker expressed her gratitude, acknowledging the contributions of her peers in the life sciences community. She stated, "This is an exciting time for Halda as we move our first therapy into the clinic in early 2025, the result of several years of groundbreaking research and the invention of RIPTAC™ therapeutics to meet unmet needs in oncology. I look forward to supporting other start-ups and growing our thriving ecosystem."
The Journey of Halda Therapeutics
As Halda's Chief Scientific Officer, Dr. Kayser-Bricker plays a pivotal role in advancing innovative cancer therapies. The company has achieved significant milestones, including securing $126 million in Series B funding, which highlights investor confidence in their groundbreaking work. Under her leadership, Halda is positioning itself at the forefront of cancer research, ready to make substantial impacts in treatment protocols.
In an era where precision medicine is becoming increasingly important, Halda Therapeutics stands as a beacon of hope for many. The company is dedicated to addressing critical gaps in cancer treatment and enhancing patient outcomes.
Recognition from the Community
Jodie Gillon, President & CEO of BioCT, also praised Dr. Kayser-Bricker’s contributions and selection by the awards committee, emphasizing her commitment to supporting underrepresented groups in the life sciences. Dr. Kayser-Bricker’s journey with Halda has been pivotal, leading to essential advancements in life science funding and innovation.
Additionally, the award ceremony brought together around 300 life science executives, showcasing the collaborative spirit of the industry while the Yale Ventures Life Sciences Pitchfest highlighted groundbreaking research projects. Both events underscore the vibrant life sciences community and the innovative capabilities rooted within.
Looking to the Future
With Halda’s expansion and a surge of positive developments across the life sciences sector, it is clear that Dr. Kayser-Bricker’s leadership will continue to inspire a new generation of innovators. Other notable successes have emerged, such as EvolveImmune Therapeutics raising $65 million for precision cancer medicines, and Modifi Bio being acquired by Merck, indicating a dynamic and successful landscape for biotechnology companies.
About Shipman & Goodwin and BioCT
Shipman & Goodwin LLP is more than just a law firm; it is a champion of diversity, equity, and community involvement. With a focus on serving local, national, and international clients, the firm remains committed to fostering an inclusive environment.
On the other hand, BioCT serves as the voice of the life sciences community, advocating for growth and innovation. Their mission is to create a more robust ecosystem by facilitating collaboration among more than 250 member companies.
Frequently Asked Questions
Who is Kat Kayser-Bricker?
Kat Kayser-Bricker, Ph.D., is the Chief Scientific Officer at Halda Therapeutics, renowned for her work in precision cancer therapies.
What is the Entrepreneur of the Year Award?
This award honors entrepreneurs who significantly contribute to the life sciences industry, enhancing innovation and community impact.
What contributions has Dr. Kayser-Bricker made to life sciences?
Dr. Kayser-Bricker has spearheaded advancements in cancer therapies and secured substantial funding to fuel innovation in oncology.
How does Shipman & Goodwin support entrepreneurs?
Shipman & Goodwin provides legal and community support for entrepreneurs, fostering growth in the life sciences sector through advocacy and mentorship.
What role does BioCT play in the life sciences sector?
BioCT is a trade organization advocating for the life sciences community, working towards innovation, growth, and collaboration among its member companies.
